S'abonner

Benefits of Physical Activity for Depression and Fatigue in Multiple Sclerosis: A Longitudinal Analysis - 23/05/19

Doi : 10.1016/j.jpeds.2019.01.040 
Samantha Stephens, PhD 1, Shahriar Shams, MSc 2, Joshua Lee, PhD 3, Stephanie A. Grover, MSc 1, Giulia Longoni, MD 1, 3, Tara Berenbaum, BSc 1, Marcia Finlayson, PhD 4, Robert W. Motl, PhD 5, E. Ann Yeh, MD 1, 3,
1 Division of Neurosciences and Mental Health, SickKids Research Institute, Division Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada 
2 Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada 
3 Faculty of Medicine, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada 
4 Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada 
5 Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL 

Reprint requests: E. Ann Yeh, MD, Division of Neurology, Department of Neurosciences and Mental Health, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G1X8, Canada.Division of NeurologyDepartment of Neurosciences and Mental HealthThe Hospital for Sick Children555 University AveTorontoOntarioM5G1X8Canada

Abstract

Objectives

To examine the longitudinal relationship between physical activity and fatigue and depression among youth with demyelinating conditions.

Study design

From September 2013 to March 2017, we performed a longitudinal study of consecutive youth diagnosed at their first visit with pediatric onset multiple sclerosis (POMS) or monophasic acquired demyelinating syndromes (mono-ADS) at a neuroinflammatory disorders clinic in a tertiary children's hospital. Fatigue was determined at each visit by the Pediatric Quality of Life Multidimensional Fatigue Scale, depressive symptoms by the Center of Epidemiologic Studies Depression Children Rating Scale, and physical activity level by the Godin Leisure Time Exercise Questionnaire. Mixed linear models were used to examine the associations of moderate-to-vigorous physical activity (MVPA) with fatigue and depression over time, adjusting for age, time from incident demyelination, sex, number of relapses, relapse within 30 days, and disability.

Results

In 182 patients (48 POMS, age 15 ± 1.7 years, 35 female; and 134 mono-ADS, age 12 ± 3.6 years 67 female) with 538 visits (mean follow-up 3.6 ± 2.7 years and 4.2 ± 3.3 years, respectively), a trajectory of increased fatigue over time was observed in POMS (2.28 points/year, P = .008) and mono-ADS (1.33 points/year, P = .007) patients. Youth with POMS had more depressive symptoms (estimate = 11.4 points, P < .002) than mono-ADS. Depressive symptoms increased over time in female patients with POMS (estimate = 1.4 points/year, P < .02). MVPA was associated with lower depression (−0.09, P < .001) and general fatigue (0.13, P = .02) over time in POMS.

Conclusions

Youth with POMS who have higher levels of MVPA demonstrate lesser depressive symptoms and lower fatigue over time. Our results may inform future interventions to manage mood and fatigue in POMS.

Le texte complet de cet article est disponible en PDF.

Keywords : exercise, pediatric, multiple sclerosis, psychosocial outcomes

Abbreviations : EDSS, Mono-ADS, MS, MVPA, PedsQL-MFS, POMS


Plan


 Supported by Multiple Sclerosis Society of Canada (EGID 2736 [to S.S.]), The Hospital for Sick Children Foundation, SickKids Research Institute, Mario Batali Foundation/National Multiple Sclerosis Society (PP 2256 [to E.Y.]), National Multiple Sclerosis Society (MB 0031 [to E.Y.]), and Centre of Brain and Mental Health at the Hospital for Sick Children. M.F. has received research funds from NMSS, CMSC, MSSC, and PCORI. R.M. has received research funds from NMSS, CMSC, NIH, and PCORI. E.Y. has received funds from NMSS, CIHI, CIHR, OIRM, SCN, CBMH, MS Society of Canada, Mario Batali Foundation, PCORI, SickKids Foundation, CBMH Innovation Fund, CMSC, Rare Disease Foundation, Biogen MA Inc., and The Guthy Jackson Charitable Foundation; serves as a relapse adjudicator for ACI; served on a scientific advisory panel for Juno Therapeutics; received a speaker's honorarium from Novartis; and received unrestricted funds from Teva for an educational symposium. The other authors declare no conflicts of interest.


© 2019  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 209

P. 226 - juin 2019 Retour au numéro
Article précédent Article précédent
  • Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets
  • Wade L. Schulz, Jacob McPadden, Eric A. Gehrie, Burak Bahar, Amit Gokhale, Rebecca Ross, Nathaniel Price, Bryan R. Spencer, Edward Snyder
| Article suivant Article suivant
  • Musculoskeletal Manifestations as Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents
  • Rachel Levy, Gil Amarilyo, Rotem Tal, Jacob Amir, Amit Assa, Firas Rinawi, Liora Harel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.